UNSPSC 51191543: Cyclopenthiazide

This classification denotes a thiazide diuretic with the molecular formula C13H18ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VX4S2N85F5, chemically known as 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-2h-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide but generally known as cyclopenthiazide, which bears US NIH Compound Identifier 2904. European Medicines Agency schedules Cyclopenthiazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06857MIG.

UNSPSC 51191543 Cyclopenthiazide, a Commodity code, nominally represents pharmaceutical products; however, the recent state and local opportunities posted against this code show minimal connection to the code's stated scope. The City of Meriden's July 2026 solicitation (B027-15) requests sodium bisulfite, a water-treatment chemical unrelated to cyclopenthiazide. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP from January 2026 addresses generic multi-source pharmaceuticals and OTC products more broadly, with no indication that cyclopenthiazide is among the targeted NDCs or therapeutic classes. State and local governments posting to this code appear to be using it as a generic pharmaceutical or chemical commodity placeholder rather than as a specific product specification. The issuing bodies documented are a municipal water authority (City of Meriden, Connecticut) and a multistate cooperative purchasing vehicle (MMCAP, administered by the Minnesota Department of Administration), representing fragmented demand across utilities and state-level health procurement functions.

Geographic activity is limited to Connecticut and Minnesota with multistate coverage through MMCAP (including Oregon participating member jurisdictions). The City of Meriden's IFB for sodium bisulfite closed July 29, 2026, requiring contractors to carry $1 million to $2 million general liability coverage and performance bonds. MMCAP's RFP for generic pharmaceuticals and OTC products, due March 26, 2026, targets manufacturers capable of supplying through AmerisourceBergen (Cencara), Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026, and carries a 3 percent administrative fee on all contract purchases. The code shows little targeted activity for cyclopenthiazide specifically and warrants verification of actual product demand before pursuit.